Form 4: SCPH CEO Tucker's Holdings Convert in MannKind Merger

scPharmaceuticals Inc. President and CEO John H. Tucker's equity holdings were converted into cash and contingent value rights following the merger with MannKind Corporation.

Summary

• John H. Tucker, President and CEO of scPharmaceuticals Inc. (SCPH), reported changes in his beneficial ownership following the completion of the merger with MannKind Corporation.
• The merger, effective October 7, 2025, resulted in scPharmaceuticals Inc. becoming a wholly-owned subsidiary of MannKind Corporation.
• Tendering stockholders received $5.35 in cash per share, plus one non-tradable contingent value right (CVR) per share, representing the right to receive one contingent payment of $1.00 in cash upon achievement of a specified milestone.
• Tucker's 318,502 shares of common stock were disposed of, and 122,345 shares were acquired (likely through conversion), resulting in zero direct beneficial ownership of scPharmaceuticals Inc. common stock post-transaction.
• His 318,502 time-based restricted stock unit (RSU) awards were fully vested, canceled, and converted into $5.35 cash per share plus one CVR per share.
• All outstanding and unexercised stock options with an exercise price less than $5.35 were canceled and converted into cash (equal to the difference between $5.35 and the exercise price) plus one CVR per share.

Sentiment

Score: 7

Explanation: The completion of the merger provides a defined cash value and potential additional upside via CVRs for shareholders, representing a successful exit for the public entity. While the company ceases independent trading, the transaction terms are generally favorable for those who tendered.

Positives

• The completion of the merger provides liquidity to former scPharmaceuticals Inc. shareholders.
• Shareholders received a cash consideration of $5.35 per share.
• Shareholders also received a contingent value right (CVR) of $1.00 per share, offering potential additional upside upon milestone achievement.
• All outstanding time-based restricted stock unit awards held by the reporting person were fully vested and converted into cash and CVRs.
• In-the-money stock options (exercise price less than $5.35) were cashed out, providing value to option holders.

Negatives

• scPharmaceuticals Inc. is no longer an independent publicly traded company.
• The contingent value right (CVR) is non-tradable, limiting liquidity for this portion of the consideration.
• Payment of the $1.00 CVR is subject to the achievement of a specified milestone, meaning there is no guarantee of receiving this additional payment.
• John H. Tucker's direct beneficial ownership of scPharmaceuticals Inc. common stock is now zero.

Risks

• The contingent value right (CVR) is non-tradable, which limits the ability of holders to sell or transfer this right.
• The payment of the $1.00 CVR is contingent upon the achievement of a specified milestone, and there is no assurance that this milestone will be met, meaning the CVR may ultimately be worth nothing.

Future Outlook

scPharmaceuticals Inc. has become a wholly-owned subsidiary of MannKind Corporation. The filing does not provide specific forward-looking statements regarding the future performance or strategic direction of the combined entity.

Industry Context

This transaction represents a consolidation within the pharmaceutical industry, where a larger entity, MannKind Corporation, has acquired scPharmaceuticals Inc. Such mergers are common for strategic growth, portfolio expansion, or to gain access to specific technologies or products.

Stakeholder Impact

• Shareholders of scPharmaceuticals Inc. received cash and contingent value rights for their shares, providing liquidity and a premium.
• Employees, including management, had their equity awards converted into cash and CVRs.
• scPharmaceuticals Inc. ceased to be an independent publicly traded entity, becoming a subsidiary of MannKind Corporation.

Next Steps

• scPharmaceuticals Inc. will continue its operations as a wholly-owned subsidiary of MannKind Corporation.

Key Dates

Recommendation

The company has been acquired and is no longer publicly traded. Existing shareholders would have tendered their shares as part of the merger, effectively selling them. There is no public market for the stock to buy or hold.

Keywords

scPharmaceuticals, SCPH, MannKind Corporation, Merger, Tender Offer, Form 4, John H. Tucker, CVR, Contingent Value Right, Equity Conversion, Stock Options, RSU, Acquisition